不可切除肝细胞癌经传统TACE达完全缓解后的术前生存预测:临床与LI-RADS MR特征评估
本研究回顾性纳入112例以TACE为一线治疗的不可切除肝细胞癌患者,分析临床与MR特征与总生存期的关联,并建立生存预测列线图。多因素Cox分析显示肿瘤边缘不光滑、瘤周强化、实性肿块内脂肪保留及BCLC分期为独立风险指标,模型AUC为0.687,高危与低危组中位生存期分别为21.6个月和34.8个月(P=0.01)。
要点
- 肿瘤边缘不光滑、瘤周强化、实性肿块内脂肪保留及BCLC分期与TACE后完全缓解的HCC患者总生存期独立相关。
- 基于上述指标构建的生存模型具有一定判别能力(AUC=0.687),可区分高危与低危患者。
- 高危组中位生存期21.6个月,低危组34.8个月,log-rank检验P=0.01。
关键影像表现/征象
- 肿瘤边缘不光滑、瘤周强化、实性肿块内脂肪保留是MR上可见的与总生存期相关的独立风险征象。
- BCLC分期也是独立风险指标,但原文未具体说明各期的分布或风险比。
诊断标准与关键数值
- 生存模型AUC为0.687,用于评估传统TACE后达完全缓解的不可切除HCC患者的总生存期。
- 高危组和低危组的中位生存期分别为21.6个月和34.8个月(log-rank检验,P=0.01)。
临床应用与阅片要点
- 对于拟行传统TACE的不可切除HCC患者,术前应关注MR上的肿瘤边缘不光滑、瘤周强化及实性肿块内脂肪保留等征象,辅助风险分层。
- 结合BCLC分期和上述MR特征可使用列线图个体化估计生存概率,但需注意模型AUC为0.687,判别能力中等。
局限性
- 回顾性研究设计。
- 单中心样本量有限(112例)。
- 原文未报告外部验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To identify the associations of clinical and magnetic resonance (MR) features with overall survival (OS) in patients with unresectable hepatocellular carcinoma (HCC) achieving complete response (CR) after conventional transcatheter arterial chemoembolization (TACE) and to further develop an individual nomograph to estimate the survival probability.
MATERIALS AND METHODS: A total of 112 patients with unresectable HCC treated with TACE as first-line treatment were retrospectively evaluated. Potential risk factors associated with OS were identified by univariate and multivariate Cox analyses. The survival model was developed by multivariate Cox proportional hazard model. The area under the receiver operating characteristic curve was calculated to assess the performance of each marker and of the whole model. Discrimination was performed using Kaplan-Meier curves, and the survival curves were compared by the log-rank test. A nomogram derived from the survival model was established.
RESULTS: Multivariate Cox analyses indicated that nonsmooth tumor margin, peritumoral enhancement, fat sparing in solid mass, and Barcelona clinic liver cancer (BCLC) stage were independent risk indicators associated with OS. The survival model showed acceptable diagnostic power, with an area under the curve (AUC) of 0.687. Kaplan-Meier curves demonstrated that the model discriminated well, as the high-risk and low-risk groups had median survival times of 21.6 months and 34.8 months, respectively (log-rank test, P = 0.01).
CONCLUSIONS: Nonsmooth tumor margin, peritumoral enhancement, fat sparing in solid mass, and BCLC stage were potential biomarkers to evaluate the survival with favorable performance and discriminate HCC patients with CR under conventional TACE treatment.
引用
- Song, Chen, Guo, et al. Preoperative estimation of the survival of patients with unresectable hepatocellular carcinoma achieving complete response after conventional transcatheter arterial chemoembolization: assessments of clinical and LI-RADS MR features. Radiol Med. 2022. PMID: 36018487. doi:10.1007/s11547-022-01517-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。